Neuro Scan AI Solutions
— PARTNERSHIPS

Build the clinical layer with us.

Neuro Scan is most useful where it will be embedded — inside hospital workflows, on the back of existing EEG hardware, in research that pushes the boundary of what cross-subject detection can do. The platform is built and dataset-validated; the next gate is live clinical deployment, and we are inside the ethics-committee review process to open it.

Current status · 2026

Mobile app and reference hardware are built. The detection engine is validated on the CHB-MIT public EEG dataset. No patient EEG has been processed in a live hospital setting yet. Ethics-committee applications have been submitted to four sites: two hospitals in Turkey, one in Helsinki, and one in the United States. Partner names will be published once each partner consents.

Clinical sites & hospitals

We are preparing a small, deliberately scoped clinical pilot program for epilepsy monitoring units (EMUs), neurocritical care units, and pediatric neurology services. The pilot will integrate with your existing 22-channel scalp EEG setup; we do not require you to change hardware.

What the pilot will provide: on-prem inference, a clinician-facing dashboard, real-time alerts to your on-call rotation, and a quarterly performance review on your site's anonymized data. What we ask in return: structured feedback, event-review under a signed DPA, and a willingness to shape a product clinicians will actually use.

Sites that are not yet under ethics review can still join the pre-pilot evaluation track: a hands-on demo at your site with our platform, no patient EEG required.

To inquire: clinical@nsai.fi — include site size, monitoring volume, and your timeline.

Research institutions

Academic groups working on EEG signal processing, seizure prediction, neuro-symbolic models, or cross-subject generalization can request access to our research SDK and validation datasets (subject to data-use agreements). We co-author when the work warrants it, and we do not gate findings behind proprietary terms when the science is fundamental.

Reach out via clinical@nsai.fi.

EEG device manufacturers (OEM)

If you build clinical or ambulatory EEG hardware, our detection engine is designed to ship inside your stack — on-device or via your cloud — under a white-label or co-branded arrangement once clinical validation closes. The model footprint is small enough to run on edge ARM hardware; integration is via a documented C API or REST. We can begin technical integration work in parallel with the ethics-approval process.

Commercial discussions: clinical@nsai.fi with subject line "OEM Inquiry."

Distributors & integrators

Once clinical validation and regulatory clearance close, we plan to work with a limited number of medical-device distributors in Europe, the United Kingdom, and North America. Distributor framework agreements — regional pricing, regulatory support, training materials, and a margin structure that reflects clinical-sales reality rather than SaaS reality — are being prepared in parallel with the ethics-approval cycle.

If you already distribute neuromonitoring or EMU equipment in your region and want to be on the shortlist for the post-pilot rollout, we want to talk: clinical@nsai.fi.

How we vet partners

We meet in person (or video) before any commitment. We share our methodology and limitations openly. We do not over-promise on regulatory timelines. If we are not a fit, we will say so in the first call.